Synthis Therapeutics

Developing a first in class therapeutic platform that rescues immune function and drives tumor clearance in advanced cancer patients

WHO WE ARE

Dynamic therapeutics immuno-oncology startup in NYC. Synthis’s team is a talented group of scientists with a groundbreaking idea to improve patient care and outcomes. As long-standing tumor immunologists, the team is passionate about the science and therapeutic power behind restoring immune function in cancer patients.

Technology

Synthis Therapeutics is an early-stage biotech company dedicated to the innovation of targeted therapies that harnesses the power of patients’ own immune system to eliminate metastatic cancer. Our novel therapeutic platform evolved from an idea to develop safer and more efficacious therapies that eliminate one of the most immunosuppressive pathways in virtually all cancers, known as TGF-β. By developing therapies that selectively target the immunosuppressive arm of the TGF-β pathway, we can safely drive efficacy and patient survival

Learn More

TIMELINE

2017

2018

2019

2020

Synthis Therapeutics was founded

& therapeutics platform biology developed virtually

Women In Bio Founders Scholarship Award

NCI Phase I SBIR Award

ELab NYC Accelerator Program Fellow

Alexandria LaunchLabs Member Company

Annual Alexandria Life Science Summit Pitch

NCI Phase I SBIR Award

J&J Innovation Showcase Company

Springboard Enterprises Life Science Track Observer

Annual BIO CEO & Investor Conference: NYC-EDC selected company

Annual BIO Conference NIH Sponsored Company Presentation

Endless Frontiers Lab Accelerator Program

CONTACT US

430 E. 29th Street
Alexandria LaunchLabs, 14th Floor
New York, New York
10016

917-837-8796